Clinical Trial

THC and Ketamine Effects in Humans

Study Description

THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis

The aim of the research protocol is to evaluate cannabinoid-glutamate interactions in humans. As part of this aim the investigators will assess the safety and tolerability of the combination of NMDA antagonist, ketamine, and the cannabinoid, delta-9-tetrahydrocannabinol (THC), in healthy adult subjects, and characterize the interactive effects of ketamine and THC on various electrophysiological (EEG), cognitive, and behavioral outcomes.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Active Delta-9-THC

Active Delta-9-THC (0.015 mg/kg) given intravenously (IV)

Drug - Placebo Delta-9-THC

A placebo dose given intravenously (IV)

Drug - Active Ketamine

Active Ketamine (0.2 mg/kg) given intravenously (IV)

Drug - Placebo Ketamine

A placebo dose given intravenously (IV)

Additional Information

Official Study Title

An Electrophysiological Examination of CB1 and NMDA Receptors in Humans

Clinical Trial ID

NCT04199468

ParticipAid ID

eVOX5a